LMB-100

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameLMB-100
Drug Alias NameRG-7787RO-6927005LMB-100
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionMesothelin inhibitors
TargetsMesothelin
Therapy Area/IndicationsPleural Effusion, MalignantCarcinoma, Non-Small-Cell LungLung Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesDenmark +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteSelecta Biosciences Inc
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsPancreatic NeoplasmsNeoplasms, MesothelialCholangiocarcinoma
Inactive IndicationsPleural Effusion, MalignantCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A